Lung cancer trials in Japan

In Japan 135 Also abroad 2746

135 trials · From ClinicalTrials.gov, checked 14 November 2026. Ask the study team whether a trial fits you.

Phase 1/2Taking people
A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types
Where
Chuo Ku, Koto-Ku
Age
18 years and over
People
182 worldwide
Run by
Eisai Inc.
See details and how to joinNCT04300556 · EU 2023-506868-14-00
Phase 1Taking people
Study With ABBV-CLS-484 in Participants With Locally Advanced or Metastatic Tumors
Where
Chuo-ku, Wakayama
Age
18 years and over
People
248 worldwide
Run by
Calico Life Sciences LLC
See details and how to joinNCT04777994 · EU 2023-507568-38-00
Phase 1/2Taking people
A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements
Where
Chuo Ku, Kashiwa, Nagoya, Osaka, Sapporo, Tōon, Yokohama, Yonago
Age
12 years and over
People
500 worldwide
Run by
Turning Point Therapeutics, Inc.
See details and how to joinNCT03093116 · EU 2024-512606-25-00
Phase 2Taking people
A Study of LP-300 With Carboplatin and Pemetrexed in Never Smokers With Advanced Lung Adenocarcinoma
Where
Chuo Ku, Okayama, Sapporo, Sendai, Yokohama
Age
18 years and over
People
90 worldwide
Run by
Lantern Pharma Inc.
See details and how to joinNCT05456256
No phaseTaking people
Survey of Brigatinib Used To Treat People With Non-Small Cell Lung Cancer
Where
Tokyo
People
500
Run by
Takeda
See details and how to joinNCT05100069
Phase 1Taking people
A PHASE I STUDY OF ALPS12 IN PATIENTS WITH EXTENSIVE STAGE SMALL CELL LUNG CANCER
Where
Kashiwa, Niigata, Sakai, Tōon
Age
18 years and over
People
122 worldwide
Run by
Chugai Pharmaceutical
See details and how to joinNCT07107490
Phase 1/2Taking people
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
Where
Chuo Ku, City
Age
18 years and over
People
27 worldwide
Run by
Tanabe Pharma America, Inc.
See details and how to joinNCT06943521
Phase 1/2Enrolling by invitation
Using CICS-1 and SPM-011 and ［18F］FBPA Commissioned by CICS and Sumitomo Heavy Industries and STELLA PHARMA
Where
Osaka
Age
18 years to 85 years
People
30
Run by
Stella Pharma Corporation
See details and how to joinNCT06603987
No phaseNot yet taking people in Japan
A Prospective Study Investigating the Relationship Between Minimal Residual Disease Detection, Monitoring Frequency, and Prognosis in Non-small Cell Lung Cancer Patients Eligible for Curative Treatment.
Where
Chuo Ku
Age
18 years and over
People
350
Run by
National Cancer Center, Japan
See details and how to joinNCT06854939
Phase 1/2Taking people
Assessment of Anti-tumor and Safety in Glumetinib in Patients With c-MET-positive Non-Small Cell Lung Cancer
Where
Ehime, Fukuoka, Kanagawa, Niigata, Osaka, Sapporo, Shizuoka, Tokyo, Tottori
Age
18 years to 80 years
People
183 worldwide
Run by
Haihe Biopharma Co., Ltd.
See details and how to joinNCT04270591